Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
Open Access
- 1 February 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (4) , 519-525
- https://doi.org/10.1038/sj.bjp.0707003
Abstract
Background and Purpose: There is increasing evidence to suggest that cannabis can ameliorate muscle‐spasticity in multiple sclerosis, as was objectively shown in experimental autoimmune encephalomyelitis models. The purpose of this study was to investigate further the involvement of CB1 and CB2 cannabinoid receptors in the control of experimental spasticity. Experimental approach: Spasticity was induced in wildtype and CB1‐deficient mice following the development of relapsing, experimental autoimmune encephalomyelitis. Spastic‐hindlimb stiffness was measured by the resistance to flexion against a strain gauge following the administration of CB1 and CB2 agonists. Key Results: As previously suggested, some CB2‐selective agonists (RWJ400065) could inhibit spasticity. Importantly, however, the anti‐spastic activity of RWJ400065 and the therapeutic effect of non‐selective CB1/CB2 agonists (R(+)WIN55,212–2 and CP55, 940) was lost in spastic, CB1‐deficit mice. Conclusions and Implications: The CB1 receptor controls spasticity and cross‐reactivity to this receptor appears to account for the therapeutic action of some CB2 agonists. As cannabinoid‐induced psychoactivity is also mediated by the CB1 receptor, it will be difficult to truly dissociate the therapeutic effects from the well‐known, adverse effects of cannabinoids when using cannabis as a medicine. The lack of knowledge on the true diversity of the cannabinoid system coupled with the lack of total specificity of current cannabinoid reagents makes interpretation of in vivo results difficult, if using a purely pharmacological approach. Gene knockout technology provides an important tool in target validation and indicates that the CB1 receptor is the main cannabinoid target for an anti‐spastic effect. British Journal of Pharmacology (2007) 150, 519–525. doi:10.1038/sj.bjp.0707003Keywords
This publication has 53 references indexed in Scilit:
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006
- Anandamide Uptake Is Consistent with Rate-limited Diffusion and Is Regulated by the Degree of Its Hydrolysis by Fatty Acid Amide HydrolaseJournal of Biological Chemistry, 2006
- UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disordersEuropean Neuropsychopharmacology, 2006
- Identification and Functional Characterization of Brainstem Cannabinoid CB2ReceptorsScience, 2005
- Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Cloning and pharmacological characterization of mouse TRPV1Neuroscience Letters, 2004
- Comparison of Anandamide Transport in FAAH Wild-Type and Knockout Neurons: Evidence for Contributions by both FAAH and the CB1 Receptor to Anandamide UptakeBiochemistry, 2004
- Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects?Journal of Pharmacy and Pharmacology, 2003
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Endocannabinoids control spasticity in a multiple sclerosis modelThe FASEB Journal, 2000